Sun Forwards Specialty Strategy With $576m Concert Acquisition
Sun’s Nabs Concert, Picking Up Firm’s ‘Potential Best-In-Class’ Deuruxolitinib
Sun has struck a $576m deal to acquire Concert Pharmaceuticals, picking up lead product candidate deuruxolitinib as part of an acquisition that advances the Indian firm’s specialty pivot.
